Medindia

X

Atrium generates strong growth during the second quarter

Thursday, August 7, 2008 General News J E 4
Advertisement
Significant increase in revenues and net earnings from continued

operations of 165% and 157% respectively



All amounts are in US dollars.



QUEBEC CITY, Aug. 7 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries, disclosed today its financial results for the second quarter of 2008.



During the quarter ended June 30, 2008, Atrium recorded revenues from continuing operations of $74.5 million, which represents an increase of 165% compared to revenues of $28.2 million for the corresponding quarter in 2007. Earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the second quarter of 2008 increased by 128% to $18.2 million compared to $8.0 million for the same period in 2007. For the quarter ended June 30, 2008, net earnings from continuing operations were $10.7 million compared to $4.2 million for the same period in 2007, an increase of 157%.

The Company's total net earnings were $43.9 million compared to net earnings of $6.6 million for the corresponding period in 2007. For the second quarter of 2008, net earnings per share on a diluted basis rose to $1.33 per share, compared to $0.20 per share for the same period in 2007. Net earnings and net earnings per share in 2008 include a net gain of $30.9 million on the sale of the AI&SC Division.

For the six-month period ended June 30, 2008, revenues from continuing operations were $140.3 million, up 119% from $64.1 million for the corresponding period in 2007. EBITDA from continuing operations for the first half of 2008 was $36.6 million, an increase of 108% compared to $17.6 million for the same period last year. For the first half of 2008, total net earnings increased by 284% to $58.6 million generating fully diluted earnings per share of $1.77, compared to $15.2 million and $0.47 per share for the first six months of 2007.

"We are extremely satisfied with our results for the second quarter, confirming the soundness of our strategic development plan. Strong organic growth exceeding our target, combined with the benefits of our recent acquisitions, allows us to be optimistic for the remainder of 2008. Moreover, completing the sale of our Active Ingredients and Specialty Chemicals Division is providing us all the financial flexibility required to pursue our growth strategy through acquisitions in the promising sector of specialties health and nutrition products," said Mr. Pierre Fitzgibbon, Atrium's President and Chief Executive Officer.

For the second quarter of 2008, cash flows from continuing operating activities, before changes in non-cash working capital items, were $12.2 million, an increase of 149% compared to $4.9 million for the same period of the preceding year. For the six-month period ended June 30, 2008, cash flows from continuing operating activities, before changes in non-cash working capital items, were $23.9 million, an increase of 115% compared to $11.1 million for the same period in 2007. As at June 30, 2008, the Company had a total debt amounting to $144 million as the Company has a revolving credit facility that provides $300 million of borrowing capacity. In addition, through an unsecured loan, the Company has additional capacity of $35.9 million that can be used in whole or in part by December 31, 2008 according to the amendment signed on May 21, 2008.



Discontinued Operations - Active Ingredients and Specialty Chemicals

(AI&SC) Division



On May 22, 2008, Atrium completed the sale of its Active Ingredients and Specialty Chemicals Division for total proceeds of $166.4 million in cash, subject to a post-closing working capital adjustment. Atrium has become a health and nutrition pure play and t
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ESBATech Raises Additional CHF 23M (USD 22M), Exte...
S
ChemBridge Research Laboratories, Inc. (CRL) has E...